Misplaced Pages

Anatumomab mafenatox is a mouse monoclonal antibody studied for the treatment non-small cell lung cancer, which acts as a tumor-targeted superantigen.

It is a fusion protein of a human tumor-associated 5T4 antigen monoclonal IgG1 Fab fragment with an enterotoxin ('mafenatox') of Staphylococcus aureus.

Development was abandoned in 2005.

References

1. "Active Biotech". activebiotech.com. Retrieved 25 May 2016.
2. Hedlund G, Forsberg G, Nederman T, Sundstedt A, Dahlberg L, Tiensuu M, Nilsson M (2013). "Tumor-Targeted Superantigens". Fusion Protein Technologies for Biopharmaceuticals. Wiley. pp. 365–381. doi:10.1002/9781118354599.ch24. ISBN 9781118354599.
3. "Drug info" (PDF). World Health Organization. Retrieved 25 May 2016.
4. "Anatumomab mafenatox". AdisInsight. Springer Nature Switzerland AG.

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Monoclonal antibodies for tumors
• Abandoned drugs
• Antibody-drug conjugates
• Monoclonal antibody stubs
• Antineoplastic and immunomodulating drug stubs